Skip to main content

Advertisement

Log in

Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study

Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

No routine coagulation laboratory test is recommended during rivaroxaban or dabigatran treatment. However measuring drug concentration and/or anticoagulant activity can be desirable in some special clinical settings, such as bleeding, thrombosis recurrence or emergency surgery. The effects of dabigatran etexilate and rivaroxaban on various coagulation assays have been previously studied in normal plasma spiked with increasing concentrations of the drug. In contrast, few data are available in routinely treated patients. In order to perform and to interpret the results of these tests, it is necessary to determine the usual responses of patient’s plasma. We have used several coagulation tests in a prospective study including 106 patients receiving thromboprophylactic treatment with dabigatran 150 or 220 mg od and rivaroxaban 10 mg od for major orthopaedic surgery. The most common tests—prothrombin time (PT) and activated partial thromboplastin time (aPTT)—give results, which vary according to the reagent used. To overcome this limitation, we advocate the use of plasma calibrators, which decreases the inter-laboratory heterogeneity of results. Anti-Xa measurement and Hemoclot, a thrombin diluted clotting assay, are specific assays which have been proposed for rivaroxaban and dabigatran respectively. These tests, conventional PT, aPTT and thrombin generation (TG) have been performed. We demonstrated that measurements of both drugs can determine reliably the drug concentration in patients’ plasmas. PT is more prolonged with rivaroxaban than with dabigatran. Interestingly, the pattern of TG was clearly different in relation to the difference in the mechanism of action of the two new anticoagulants. A significant inter-individual variability of response is detected. Rivaroxaban—mean Cmax 140 ng/mL (extremes 0–412) induces a greater increase of PT than dabigatran. aPTT is sensitive to dabigatran. Rivaroxaban concentrations were in good agreement with two other studies while unexplained lower than expected concentrations were found in dabigatran patients receiving 220 mg once a day [mean Cmax 60 ng/mL (extremes 0–320)]. An interference by pantoprazole, a drug which reduces dabigatran absorption, could explain the observed lower than expected results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151

    Article  PubMed  CAS  Google Scholar 

  2. ROCKET AF Study Investigators (2010) Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 159(340–347):e1

    Google Scholar 

  3. Samama MM, Martinoli JL, Le Flem L, Guinet C, Plu-Bureau G, Depasse F (2010) Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor. Thromb Haemost 103:815–825

    Article  PubMed  CAS  Google Scholar 

  4. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (2010) Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127

    Article  PubMed  Google Scholar 

  5. Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F (2010) An optimized, rapid chromogenic assay, specific of measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost 104:1078–1079

    Article  PubMed  CAS  Google Scholar 

  6. Freyburger G, Macouillard G, Labrouche S, Sztark F (2011) Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 127:457–465

    Article  PubMed  CAS  Google Scholar 

  7. Jungbauer L, Dobias C, Stöllberger C, Weidinger F (2010) The frequency of prescription of P-glycoprotein-affecting drugs in atrial fibrillation. doi:10.1111/j.1538-7836.2010.03943.x

    Google Scholar 

  8. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Le Flem L, Rohde G, Martinoli JL (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107:379–387

    Article  PubMed  CAS  Google Scholar 

  9. Samama MM, LeFlem L, Guinet C, Gerotziafas G, Depasse F (2007) Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thromb Haemost 5:2554–2556

    Article  PubMed  CAS  Google Scholar 

  10. Wagenvoord RJ, Deinum J, Elg M, Hemker HC (2010) The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by alpha-macroglobulin-thrombin. J Thromb Haemost 8:1281–1289

    Article  PubMed  CAS  Google Scholar 

  11. Huisman MV, Lip GYH, Diener HC, Brueckmann M, Van Ryn J, Clemens A (2012) Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 107:838–847

    Article  PubMed  CAS  Google Scholar 

  12. European medicines Agency. Committee for Medicinal products for Human Use (CHMP) Assessment report for Pradaxa. 9 June 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assesment_Report_-_Variation/human/000829/WC500110875.pdf. Accessed 24 November 2011

  13. Tripodi A, Chantarangkul V, Guinet C, Samama MM (2011) The INR calibrated for rivaroxaban-(INRrivaroxaban) has the potential to normalize PT results for rivaroxaban-treated patients. Results of an in vitro study. J Thromb Haemost 9:226–228

    Article  PubMed  CAS  Google Scholar 

  14. Samama MM, Contant G, Spiro TE, Perzborn E, LeFlem L, Guinet C, Gourmelin Y, Martinoli JL (2012) Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 18:150–158

    Article  PubMed  CAS  Google Scholar 

  15. Mani H, Hesse C, Stratmann G, Lindhoff-Last E (2011) Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 106:156–164

    Article  PubMed  CAS  Google Scholar 

  16. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F (2011) Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 50:675–686

    Article  PubMed  CAS  Google Scholar 

  17. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kalebo P, Muelhofer E, Misselwitz F, Eriksson BI (2008) Population pharmacokinetics and pharmacodynamics of once and twice daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100:453–461

    PubMed  CAS  Google Scholar 

  18. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM (2012) Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 107:985–997

    Article  PubMed  CAS  Google Scholar 

  19. Legrand M, Mateo J, Aribaud A, Ginisty S, Eftekhari P, Tran Ba Huy P, Drouet L, Payen D (2011) The use of dabigatran in elderly patients. Arch Intern Med 171:1285–1286

    Article  PubMed  Google Scholar 

  20. Lillo-Lelouet A, Wolf M, Soufir L, Galbois A, Dumenil AS, Offenstadt G, Samama MM (2012) Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation. Thromb Haemost 108(3). doi:10.1160/TH12-03-0149

  21. Stangier J, Stähle H, Rathgen K, Fuhr R (2008) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47:47–59

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors thank Dr. Earle Rothbell (Colonia, New Jersey, USA) for his help in the revision of this manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Meyer Michel Samama.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Samama, M.M., Guinet, C., Le Flem, L. et al. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis 35, 140–146 (2013). https://doi.org/10.1007/s11239-012-0803-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-012-0803-x

Keywords

Navigation